Entropy Neurodynamics Limited
ENP
주식 순위
#26196
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical... Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.
주가
$0.02468497
마지막 동기화: 2026-07-30
시가총액
$40.28M
변동 (1일)
0.00%
변동 (1년)
-56.08%
국가
AU
거래 Entropy Neurodynamics Limited (ENP)
카테고리
Healthcare
의 시가총액 Entropy Neurodynamics Limited(ENP)
시가총액: $40.28M
October 2026 기준으로 Entropy Neurodynamics Limited의 시가총액은 $40.28M입니다. 이는 당사 데이터에 따르면 Entropy Neurodynamics Limited이 세계에서 26196th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2021부터 2026까지 Entropy Neurodynamics Limited의 시가총액 기록
